Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Randomized, Open-label, Parallel-group, Active Controlled Study for the Efficacy and Safety of Pegylated Recombinant Consensus Interferon Variant Solution for Injection in the Treatment of Chronic Hepatitis C

NCT01903278 is registered in ClinicalTrials.gov with Beijing Kawin Technology Share-Holding Co., Ltd. as lead sponsor.

NCT NCT01903278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01903278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Randomized, Open-label, Parallel-group, Active Controlled Study for the Efficacy and Safety of Pegylated Recombinant Consensus Interferon Variant Solution for Injection in the Treatment of Chronic Hepatitis C
Lead sponsor
Beijing Kawin Technology Share-Holding Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2013
Completion date
August 31, 2015
Enrollment
719 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c